Ignite Creation Date:
2024-05-05 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00105092
Status:
COMPLETED
Last Update Posted:
2007-05-01
First Post:
2005-03-04
Brief Title:
Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Non-Small-Cell Lung Carcinoma |
Keywords: